Liquidia Technologies (NASDAQ:LQDA) Given New $31.00 Price Target at Wells Fargo & Company

Key Points

• Wells Fargo & Company has raised its price target for Liquidia Technologies from $25.00 to $31.00, indicating a potential upside of 28.63% based on the company's previous close.
• Despite the price target increase from Wells Fargo, other analysts have varied opinions, with Bank of America lowering its price objective to $23.00, while Needham & Company and HC Wainwright set higher targets of $36.00 and $35.00 respectively.
• Liquidia Technologies recently reported a revenue increase of 141.5% year-over-year, although it posted a loss of ($0.49) EPS, missing consensus estimates.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) had its price target boosted by analysts at Wells Fargo & Company from $25.00 to $31.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Wells Fargo & Company's target price points to a potential upside of 28.63% from the company's previous close.

LQDA has been the subject of several other reports. Bank of America cut their price objective on shares of Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating for the company in a report on Wednesday, June 11th. BTIG Research reaffirmed a "buy" rating on shares of Liquidia Technologies in a report on Tuesday, May 27th. Needham & Company LLC boosted their price objective on Liquidia Technologies from $32.00 to $36.00 and gave the company a "buy" rating in a research note on Tuesday. HC Wainwright boosted their price objective on Liquidia Technologies from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, May 28th. Finally, Scotiabank boosted their price objective on Liquidia Technologies from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research note on Wednesday, May 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $28.78.

Liquidia Technologies Stock Up 13.7%

LQDA stock opened at $24.10 on Wednesday. The stock has a fifty day moving average of $15.83 and a 200-day moving average of $15.29. Liquidia Technologies has a fifty-two week low of $8.26 and a fifty-two week high of $24.83. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -15.25 and a beta of 0.14. The company has a debt-to-equity ratio of 2.08, a quick ratio of 2.91 and a current ratio of 2.93.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.06). The business had revenue of $8.84 million for the quarter, compared to analysts' expectations of $3.90 million. Liquidia Technologies had a negative net margin of 903.80% and a negative return on equity of 177.91%. The firm's revenue was up 141.5% compared to the same quarter last year. As a group, equities research analysts predict that Liquidia Technologies will post -1.51 earnings per share for the current year.

Insider Activity at Liquidia Technologies

In other Liquidia Technologies news, insider Rajeev Saggar sold 2,526 shares of the firm's stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $14.54, for a total value of $36,728.04. Following the sale, the insider owned 268,887 shares of the company's stock, valued at $3,909,616.98. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Roger Jeffs sold 20,252 shares of Liquidia Technologies stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $289,198.56. Following the sale, the chief executive officer owned 1,038,560 shares of the company's stock, valued at approximately $14,830,636.80. This trade represents a 1.91% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,277 shares of company stock worth $1,469,392 in the last 90 days. 30.10% of the stock is owned by company insiders.

Institutional Trading of Liquidia Technologies

A number of large investors have recently modified their holdings of LQDA. Geode Capital Management LLC boosted its position in shares of Liquidia Technologies by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock valued at $15,753,000 after acquiring an additional 101,597 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Liquidia Technologies by 69.1% during the 4th quarter. Wells Fargo & Company MN now owns 30,020 shares of the company's stock valued at $353,000 after acquiring an additional 12,267 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Liquidia Technologies during the 4th quarter valued at about $952,000. Invesco Ltd. boosted its position in shares of Liquidia Technologies by 2,675.0% during the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company's stock valued at $8,234,000 after acquiring an additional 674,940 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Liquidia Technologies by 6.5% during the 4th quarter. Legal & General Group Plc now owns 83,286 shares of the company's stock valued at $979,000 after acquiring an additional 5,048 shares during the last quarter. Institutional investors own 64.54% of the company's stock.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.